BridGene Biosciences has raised $38.5m in Series B financing round for the development of its next generation chemoproteomic platform, Isobaric Mass Tagged Affinity Characterization (IMTAC), as well as oncology drugs.
The US Food and Drug Administration (FDA) has approved QBiotics Group’s Investigational New Drug (IND) application to commence the Phase II clinical trial (QB46C-H07) of tigilanol tiglate.
Sunnybrook Research Institute (SRI) and Amylyx Pharmaceuticals have joined forces to develop new drug candidates to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
SK Biopharmaceuticals and Brazilian pharmaceutical firm Eurofarma have signed a license agreement to develop and commercialise cenobamate to treat epilepsy in Latin America.
Inspirna has raised $50m in Series D financing round to advance the development of its clinical stage cancer drugs.
WuXi XDC has signed a Memorandum of Understanding (MOU) with Korean biotechnology firm AbTis to develop and manufacture a portfolio of antibody-drug conjugates (ADC) products.
Exelixis has signed an exclusive license agreement with Ryvu Therapeutics to develop new targeted cancer therapies.
Turnstone Biologics has formed a broad strategic alliance with Moffitt Cancer Center for advancing the development of next-generation tumour-infiltrating lymphocyte (TIL) therapies for solid tumours.
UK-based Mogrify has collaborated with Astellas Pharma to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss.
Regeneron Pharmaceuticals has completed the purchase of Sanofi's stake in cancer drug Libtayo (cemiplimab).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.